Aclaris Therapeutics, Inc. — FY2016 Form 10-K Summary
Business context and reporting period
Aclaris is a clinical-stage biotechnology company focused on dermatology. The filing covers the fiscal year ended December 31, 2016; quarterly data for the fourth quarter is also disclosed. The company had no approved products and no product revenue.
- Lead program: A-101 40% Topical Solution for seborrheic keratosis (SK).
- Other programs: A-101 45% for common warts and JAK inhibitors ATI-50001 and ATI-50002 for alopecia areata and potentially other dermatologic conditions.
- Two pivotal Phase 3 SK trials and one open-label safety trial were completed in 2016. The company submitted an NDA for A-101 40% in February 2017 and planned an EU MAA in the second half of 2017.
Financial performance and liquidity
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $33.5 million | $15.3 million | +$18.1 million |
| General and administrative expense | $15.1 million | $5.3 million | +$9.8 million |
| Total operating expenses | $48.6 million | $20.7 million | +$27.9 million |
| Loss from operations | $(48.6) million | $(20.7) million | $(27.9) million |
| Net loss | $(48.1) million | $(20.6) million | $(27.5) million |
| Net loss per share | $(2.25) | $(3.79) | Improved per share due primarily to share issuance |
| Cash used in operating activities | $(34.6) million | $(20.4) million | $(14.2) million |
- Liquidity: Cash, cash equivalents and marketable securities totaled $174.1 million at December 31, 2016, including $30.2 million of cash and cash equivalents and $144.0 million of marketable securities.
- Working capital: $132.3 million; total assets were $176.1 million and total liabilities were $6.6 million.
- Debt: The filing reports no material debt or ongoing financing commitments. Contractual obligations primarily comprised operating leases and Vixen annual payments totaling $1.7 million.
- Cash flow: Financing activities provided $116.8 million, consisting mainly of $18.5 million from a June 2016 private placement and $98.2 million from a November 2016 follow-on offering. Investing activities used $61.9 million, largely for purchases of marketable securities.
- Margins: Gross margin and operating margin are not meaningful because the company had no revenue; operating expenses equaled the operating loss.
- Accumulated deficit was $90.9 million at year-end. Stockholders’ equity was $169.5 million.
Material changes versus the prior comparable period
- R&D spending more than doubled, primarily because of higher A-101 40% SK development costs, expanded JAK inhibitor development, increased headcount and stock-based compensation.
- G&A expense increased primarily due to higher personnel and stock-based compensation, public-company costs, Vixen-related legal and patent expenses, market research and a $0.3 million A-101 milestone payment.
- Net loss increased substantially, while loss per share improved because the weighted-average share count increased to 21.4 million from 6.1 million.
- The company acquired Vixen Pharmaceuticals in March 2016 for $0.6 million in cash, 159,420 shares of common stock valued at approximately $2.4 million, and additional annual and contingent obligations. The acquired intellectual property was expensed as research and development.
- Shares outstanding increased to 26.1 million at December 31, 2016 from 20.2 million at December 31, 2015, reflecting equity financing and acquisition-related issuance.
Clinical progress, outlook and key risks
- In the two pivotal Phase 3 SK trials, A-101 40% achieved statistically significant improvements over vehicle. Complete clearance of all four target lesions was 4.0% versus 0% in one trial and 7.8% versus 0% in the other. No treatment-related serious adverse events were reported across the three Phase 3 trials.
- The company reported statistically significant Phase 2 results for A-101 45% in common warts and planned two additional Phase 2 trials in adult and pediatric populations.
- ATI-50001 entered clinical development; the company planned additional Phase 2 development for ATI-50001 and an IND submission and Phase 2 trial for ATI-50002 in 2017.
- Management expected existing cash, cash equivalents and marketable securities to fund operations and capital needs for more than 12 months from the financial statement issuance date, based on current assumptions. Additional capital is expected to be needed for commercialization and potential acquisitions or licensing transactions.
- Commercial success for A-101 40% depends significantly on patients paying out of pocket because SK procedures are generally not reimbursed. The company also planned to build U.S. sales, marketing and distribution capabilities.
- Manufacturing is outsourced, including API supply, applicator assembly and finished-product packaging. The company has no manufacturing facilities or personnel and lacks redundant supply sources for certain components.
- Major risks include clinical or regulatory failure, additional trial requirements, manufacturing or supply interruptions, competition, patent challenges, dependence on third parties, dilution from future financing, and inability to achieve profitability.
- Contingent obligations include up to $80.0 million in Rigel pre-commercialization milestones plus $10.0 million in additional development milestones, Vixen milestones of up to $18.0 million pre-commercialization and $22.5 million commercial, and other licensing milestones and royalties.
Important facts for investors to verify
- FDA acceptance, review status and eventual action on the A-101 40% NDA submitted in February 2017.
- Regulatory timing and results for the planned EU MAA and additional A-101 45%, ATI-50001 and ATI-50002 trials.
- Actual cash burn and whether the reported cash runway remains adequate as commercialization spending increases.
- Patient and dermatologist adoption of an SK treatment that is generally cash-pay and may not receive third-party reimbursement.
- Manufacturing readiness, supplier concentration and any required changes to the PeroxyChem or applicator supply arrangements.
- Patent durability and freedom-to-operate, particularly because certain A-101 patents begin expiring in 2022.
- Potential dilution and the timing and terms of future equity, debt, collaboration or licensing financings.